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Context: The apolipoprotein E ε4 (APOE ε4) allele is a
genetic risk factor for Alzheimer disease. Recently, de-
pression has also become recognized as a risk factor for
dementia. However, the possible effect of theAPOE geno-
type on the association between depression and demen-
tia is unexamined.
Objective: To examine the independent and com-
bined effects of depression and APOE ε4 on the risk of
dementia and its subtypes.
Design: The Honolulu-Asia Aging Study, a population-
based prospective cohort study of JapaneseAmericanmen.
Settings and Participants: Depressive symptoms and
presenceof theAPOE ε4allelewere assessedbetweenMarch
1991 and October 1993 in 1932 cognitively healthy men
aged 71 to 90 years. Incident cases of dementia were diag-
nosed during approximately 6 years of follow-up based on
neurologic assessment at 2 repeated examinations (April
1994-April 1996 and October 1997-February 1999).
Main OutcomeMeasures: Overall dementia, Alzhei-
mer disease, and vascular dementia.
Results: The interaction of depression and APOE ε4
was statistically significant in the analytical models.
Compared with men with neither APOE ε4 nor depres-
sion, the risk of dementia in nondepressed men with
APOE ε4 was not significant (hazard ratio, 1.1; 95%
confidence interval [CI], 0.6-1.8); however, depressed
men without APOE ε4 had a 1.6-fold greater risk (95%
CI, 0.8-3.0), whereas depressed men with APOE ε4 had
a 7.1-fold greater risk (95% CI, 3.0-16.7) of dementia.
For subtypes, we found similar increased risks of Alz-
heimer disease.
Conclusions: The APOE ε4 status modifies the associa-
tion between depressive symptoms and dementia in el-
derly men. Because individuals with depressive symp-
toms and the APOE ε4 allele had a markedly increased
risk of dementia, one might be especially watchful for
early signs of dementia in the older person with depres-
sion who is also positive for the APOE ε4 allele. Because
this cohort includes only men, further investigation in
women is required.
Arch Gen Psychiatry. 2008;65(8):906-912
D EPRESS ION I S OFTENfound before or as a co-existing condition withAlzheimer disease (AD),and the presence of de-
pression affects patient outcomes.1 Al-
though depression has been considered to
be a response to cognitive decline or an
early manifestation of dementia,1 results
of prospective studies2-4 and of a recent
meta-analysis5 suggest that depression
could be a potential risk factor for demen-
tia. The pathologicmechanism linking de-
pression and subsequent dementia is not
well understood, but hypotheses include
an indirect neurotoxic effect of depres-
sionmediated by cortisol-induced hippo-
campal atrophy or lowered brain-derived
neurotrophic factor levels.1 In addition,
there may be genetic links between de-
pression and dementia. The apolipopro-
tein E ε4 (APOE ε4) allele leads to accel-
erated deposition of amyloid6 and is a
major genetic risk factor for AD. The as-
sociation between APOE ε4 and depres-
sion has been examined, but the findings
are inconsistent.7-10 This genotype is a pos-
sible genetic factor that may affect the de-
pression-dementia association, but the
joint effect of depression and APOE geno-
types on dementia is unknown.Herein, we
hypothesize that the presence of both
APOE ε4 and depression leads to a greater
risk of dementia than either factor alone.
To examine this hypothesis, we investi-
gated the independent and joint effects of
depression and APOE ε4 on incident de-
mentia in a well-characterized cohort of
Author Affiliations are listed at
the end of this article.
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men participating in the Honolulu-Asia Aging Study
(HAAS).
METHODS
The HAAS was designed to investigate neurodegenerative dis-
eases in old age. This cohort was originally from the Honolulu
Heart Program study,11 which commenced in October 1965 as
a longitudinal study of risk factors for cardiovascular disease.
The cohort consists of Japanese American men born between
1900 and 1919 and living on the island of Oahu, Hawaii, at the
initial examination (October 1965-November 1968). TheHAAS
was initiated at the fourth examination of the Honolulu Heart
Program Study, inMarch 1991 to October 1993, when themen
ranged in age from 71 to 93 years.12,13 This study is based on
the March 1991 to October 1993 examination and 2 consecu-
tive follow-up examinations (April 1994-April 1996 and Oc-
tober 1997-February 1999), in which final diagnoses for cases
of dementia are available and fully validated. The study was ap-
proved by the institutional review committee of Kuakini Medi-
cal Center. All the participants were informed about the study
objectives and provided written informed consent.
ANALYTICAL SAMPLE
Of 3734 participants at the baseline examination, 1932 were
included in the analytical sample. We excluded 226 men with
prevalent dementia. Because depressive symptoms may be an
early manifestation of dementia, 982 men who were possibly
cognitively impaired (62 with a Clinical Dementia Rating score
of 0.5 and 920 with a baseline Cognitive Abilities Screening In-
strument score of82) were excluded. We also excluded 176
menwith incomplete information for depression symptoms and
APOE genotypes, 85 men who died before the first follow-up
examination, and 333 men who did not attend the follow-up
examinations.We compared the baseline characteristics of the
1932 study participants and the 1802 men excluded from the
analysis (Table 1). Men who were excluded were older, had
less education, had higher midlife blood pressure, had a lower
body mass index (BMI) (calculated as weight in kilograms di-
vided by height in meters squared), had lower total choles-
terol levels, were more likely to have smoked, and had a higher
percentage of abnormal ankle-brachial index (ABI) scores (more
atherosclerotic change) compared with men who were in-
cluded in the analysis. There were no significant differences
between the analytical sample and excluded individuals re-
garding midlife diastolic blood pressure, prevalence of diabe-
tes mellitus, and percentage who were APOE ε4 positive. Be-
cause we excluded prevalent dementia and possible dementia
cases, we expected that there would be some baseline differ-
ences between the analytical and excluded samples on the risk
factors for dementia based on studies previously reported.14 The
mean follow-up was 6.1 years, with an incidence rate for de-
mentia of 9.2 per 1000 person-years.
DIAGNOSIS OF DEMENTIA
Individuals with dementia were identified via screening for cog-
nitive function following a rigorously standardized study pro-
tocol. The 3-stage procedure has previously been described in
detail.13 Initial screening considered a participant’s age and cog-
nitive performance on the 100-point Cognitive Abilities Screen-
ing Instrument, which is a brief, comprehensive measure of
intellectual function developed and validated for use in cross-
cultural studies.15 The Cognitive Abilities Screening Instru-
ment is a composite of the Hasegawa Dementia Screening Scale
(widely used in epidemiologic studies in Japan), the Folstein
Mini-Mental State Examination, and the Modified Mini-
Mental State Examination. The score range is 0 to 100, with
higher scores indicating better cognitive function.15 The
Cognitive Abilities Screening Instrument scores were used to
identify a subsample for further diagnostic evaluation. The de-
mentia evaluation at all the examinations included a neuro-
psychological investigation, a proxy interview, a neurologic ex-
amination, neuroimaging, and selected blood tests. Final
diagnoses were assigned by a consensus panel consisting of a
neurologist (G.W.R.) and additional physicians (K.H.M., H.P.,
and L.R.W.) with expertise in dementia. Dementia was diag-
nosed according to criteria from the DSM-III-R.16 The diagno-
sis of AD was adjudicated according to the National Institute
of Neurological and Communicative Disorders and Stroke–
Alzheimer Disease and Related Disorders Association crite-
ria.17 Alzheimer disease was defined to include cases of demen-
tia in which AD was judged to be the sole or primary cause.
For the diagnosis of vascular dementia, the State of California
Alzheimer’s Disease Diagnostic and Treatment Centers crite-
ria18 were used. Vascular dementia included cases in which a
vascular cause was considered the sole or primary cause. The
remaining subtypes included subdural hematoma, Parkinson
disease, cortical Lewy body disease, Pick disease, and un-
known causes.
DEPRESSION SYMPTOMS ASSESSMENT
AND APOE GENOTYPING
Depression symptoms at the baseline examination of the HAAS
were examined in participants by using an 11-item version of
the Center for Epidemiologic Studies Depression Scale.19 Scores
range from 0 to 33, and a depression score was valid only if
there were fewer than 3 missing answers. Men with scores of 9
or greater were defined as having depressive symptoms, and
men with scores of less than 9 were defined as not having de-
Table 1. Baseline Characteristics of the Study Participants
vs Those Excluded From the Analysis
Included
Men
(n=1932)
Excluded
Men
(n=1802)
P
Valuea
Age, mean (SD), y 76.3 (3.6) 79.5 (5.1) .001
Education 6 y, % 96.8 89.1 .001
Midlife BP, mean (SD),
mm Hg
Systolic 130.7 (17.6) 133.1 (16.9) .001
Diastolic 82.3 (8.8) 82.9 (8.5) .07
Body mass index, mean
(SD)b
23.6 (3.1) 23.2 (3.0) .001
Diabetes mellitus, % 34.2 36.6 .15
Total cholesterol, mean (SD),
mg/dL
192.2 (30.8) 186.8 (33.9) .001
Never smoked, % 39.5 35.4 .02
Ankle-brachial index 0.9, % 7.6 13.4 .001
Stroke, % 7.1 15.6 .001
APOE ε4 allele positive, %c 17.6 19.6 .14
Abbreviations: APOE ε4, apolipoprotein E ε4; BP, blood pressure.
SI conversion factor: To convert cholesterol to millimoles per liter, multiply
by 0.0259.
aP values are from linear (continuous variables) and logistic (categorical
variables) regression models and are adjusted for age at baseline.
bCalculated as weight in kilograms divided by height in meters squared.
cAPOE ε4 allele positive is defined as having at least 1 copy of the
ε4 allele.
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pressive symptoms.19 In this article, we refer to the presence
of depressive symptoms as “depression” or “depressed”; how-
ever, note that these terms are not synonymous with clinically
diagnosed depression.
The APOE genotyping was performed by means of poly-
merase chain reaction amplification followed by restriction en-
zyme digestion20 at the BryanAlzheimer’s Disease ResearchCen-
ter at Duke University, Durham, North Carolina. Participants
were categorized as APOE ε4 positive if they had at least 1 copy
of the ε4 allele and as ε4 negative otherwise.
COVARIATES
Age and years of education were obtained at the baseline ex-
amination of the HAAS (1991-1993). Midlife and late-life car-
diovascular risk factors that may affect brain and depression
symptoms were adjusted for in the statistical models. Midlife
systolic and diastolic blood pressures were based on the aver-
age values measured during 3 examinations of the Honolulu
Heart Program study (1965-1968, 1967-1970, and 1971-
1974). The averaged values from the examinations were cal-
culated for the analysis. Midlife cigarette smoking status was
based on standard questions administered at these examina-
tions and was coded as never, past, or current smoker.
Late-life variables—the presence of type 2 diabetes melli-
tus, cholesterol level, BMI, and ABI—were measured in 1991-
1993, the baseline examination of the HAAS. The presence of
type 2 diabetes mellitus was assessed by participant report of a
physician’s diagnosis, the use of diabetes medications, or glu-
cose tolerance testing results. Total cholesterol levels weremea-
sured using an Autoanalyzer 1 N24B.11 The ABI, an indicator
of subclinical atherosclerosis, was dichotomized at a cutoff point
of 0.9, with values less than 0.9 considered to be indicative of
peripheral artery disease.21 Previous stroke events were as-
sessed by means of self-report and continuous surveillance of
hospital discharge on Oahu.
The level of self-reported memory problems at the baseline
of the HAASwas also assessed. Participants were askedwhether
they had noticed changes during the past 10 to 20 years in their
ability to remember the names of people they had just met, the
faces of people they had just met, the names of close friends or
relatives, or appointments. Each itemwas scored on a scale from
1 to 5 (1 indicates definitely improved; 2, slightly improved;
3, no change; 4, slightly deteriorated; and 5, definitely dete-
riorated). The average score based on the 4 items was calcu-
lated as a self-reported memory complaints rating of 1 to 5.
STATISTICAL ANALYSIS
Hazard ratios (HRs) for the incidence of dementia and its sub-
types were estimated using Cox proportional hazards models
adjusted for the covariates described in the previous subsec-
tion. In the standard model, we adjusted for age at baseline,
years of education, and awareness ofmemory problems at base-
line. In the extended model, we further adjusted for cardio-
vascular risk factors. We first investigated the estimated risks
of dementia and its subtypes in depressed men compared with
nondepressedmen. Dementia and its subtypes include all types
of dementia (all dementia), AD without cerebrovascular dis-
ease (pure AD), vascular dementia, andAD including thosewith
cerebrovascular disease (mixed AD). The interaction between
depression and APOE ε4 was investigated by including an in-
teraction term (depression  APOE ε4) in the models.
We also estimated theHRs for dementia across 4 groups based
on depression status at baseline and APOE ε4 status: menwith-
out depression and without APOE ε4 (neither), men without
depression and with APOE ε4 (only e4), depressed men with-
out APOE ε4 (only Dep), and depressed men with APOE ε4
(both). The baseline characteristics of the study sample were
compared across these 4 strata. Linear regression for continu-
ous variables and logistic regression for categorical variables
were performed, with adjustment for age. To calculate the age-
adjusted P value for trends across groups, given that the or-
dering of the 4 groups (neither, only e4, only Dep, and both)
is arbitrary in relation to only e4 and only Dep, we combined
men with only 1 risk factor, either depression or APOE ε4, into
1 group (single) and created 3 variables with the codes 0, 1,
and 2 for neither, single (only e4 and only Dep), and both, re-
spectively. This method enabled us to conduct trend analysis
across groups. All analyseswere conducted using statistical soft-
ware (Stata 8; StataCorp, College Station, Texas, and SAS ver-
sion 8.2; SAS Institute Inc, Cary, North Carolina). P .05 was
considered statistically significant, and all tests were 2-tailed.
RESULTS
Baseline characteristics across the 4 groups (neither, only
e4, only Dep, and both) are given in Table 2. The age-
adjusted incidences of dementiawere 4.2% (neither), 6.3%
(only e4), 9.3% (only Dep), and 13.7% (both). No sig-
nificant difference existed across groups ofmenwith nei-
ther risk factor, with a single risk factor, and with both
risk factors regarding age at baseline, primary educa-
tional level, diabetesmellitus, stroke history, midlife sys-
tolic and diastolic blood pressure, cholesterol level, and
BMI. However, there was a significant difference across
groups regarding abnormal ABI values, indicating that
men with both risk factors had the highest frequency of
generalized atherosclerosis.
The survival analysis consisted of 2 parts. In the first
part, we estimated the risk of dementia in depressedmen
compared with nondepressed men. The HR in de-
pressed men was approximately 2- to 3-fold greater for
all dementia, pure AD, and mixed AD. This association
remained after further adjustment of cardiovascular risk
factors (Table 3).We also included the interaction term
(depression APOE ε4 allele) in the models and found
a significant interaction effect for all dementia, pure AD,
and mixed AD (P .01 for all).
In the second part of the survival analysis, the 4 groups
were examined. The cumulative hazard estimate curves
and the log-rank test for equality of survivor function
(23=27.55, P .001) indicated a different risk of demen-
tia across the groups (Figure). Compared with men
with neither APOE ε4 nor depression, depressed men
without APOE ε4 had a 1.6-fold greater risk (95% con-
fidence interval [CI], 0.8-3.0), whereas depressed men
with APOE ε4 had a 7.1-fold greater risk (95% CI, 3.0-
16.7) (Table 4). The risk of dementia in nondepressed
men with APOE ε4 was not significant (HR, 1.1; 95%CI,
0.6-1.8). We found similar increased risks of AD and
mixed AD.
COMMENT
We examined the independent and joint effects of de-
pressive symptoms and a genetic risk factor on demen-
tia and its subtypes using dementia-free survival analy-
sis. The main finding in this study is that APOE status
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modified the association between depressive symptoms
and overall dementia, and its subtypes AD andmixedAD,
such that elderly men with the APOE ε4 allele and de-
pressive symptoms were at a several-fold greater risk for
dementia than were men who were nondepressed and
without the ε4 allele andmenwith only depressive symp-
toms and men with only the APOE ε4 allele. In the first
analysis, we confirmed that the risk of dementia in men
with depressive symptomswas approximately 2 to 3 times
higher than that in nondepressed men. Because the in-
teraction effects of depression andAPOE ε4 genotypewere
statistically significant, we further examined the inde-
pendent and combined risks of the presence of depres-
sive symptoms and APOE status on incident dementia.
Under the condition in which both factors exist, the risk
of dementia was enhanced multiplicatively rather than
additively. The enhanced hazard risk in depressed men
with the APOE ε4 genotype remained statistically sig-
nificant even after adjustment for a variety of cardiovas-
cular risk factors.
To our knowledge, the interaction effect between de-
pression and theAPOE genotype on dementia has not pre-
viously been reported, although a recent study22 from the
Mayo Clinic indicated a synergistic interaction between
depression andAPOE genotype on cognitive decline. The
independent risk on dementia in the present cohort is
higher in men who have depressive symptoms than in
those with the ε4 allele.
Several mechanisms have been proposed to account
for the association between depression and dementia.
First, late-onset depressionhas been considered as an early
manifestation of AD, and a recent postmortem study23
found increased AD neuropathologic findings in pa-
tients with late-onset depressionwithout clinical demen-
Table 2. Baseline Characteristics by Groupa
Neither
(n=1439)
Only e4
(n=324)
Only Dep
(n=146)
Both
(n=23)
P
Valueb
Age at baseline, examination 4, mean (SD), y 76.3 (3.6) 76.1 (3.6) 76.2 (3.2) 75.7 (2.2) .37
Education 6 y, % 97.8 97.5 97.1 96.7 .27
Midlife BP, mean (SD), mm Hg
Systolic 129.8 (15.2) 130.2 (9.0) 130.7 (10.9) 131.2 (7.2) .27
Diastolic 82.3 (7.6) 82.7 (5.4) 83.0 (7.2) 83.4 (4.3) .25
Body mass index, mean (SD)c 23.9 (3.8) 23.8 (1.8) 23.6 (2.4) 23.5 (1.4) .28
Diabetes mellitus, % 34.5 34.3 34.2 34.1 .77
Total cholesterol, mean (SD), mg/dL 193.3 (30.3) 193.2 (18.0) 193.1 (23.0) 193.0 (14.4) .44
Never smoked, % 36.7 38.4 40.1 41.9 .34
Ankle-brachial index 0.9, % 6.3 8.2 10.7 13.9 .03
Stroke, % 6.4 7.8 9.3 11.1 .54
Dementia incidence, % 4.2 6.3 9.3 13.7 .004
Abbreviation: BP, blood pressure.
SI conversion factor: To convert cholesterol to millimoles per liter, multiply by 0.0259.
aNeither refers to men without depressive symptoms and apolipoprotein E ε4 (APOE ε4) negative; only e4, men without depressive symptoms and APOE ε4
positive; only Dep, men with depressive symptoms and APOE ε4 negative; and both, men with depressive symptoms and APOE ε4 positive.
bP values are from linear (continuous variables) and logistic (categorical variables) regression models for 3 groups (neither, single [combined only e4 and only
Dep], and both) and are adjusted for age at baseline.
cCalculated as weight in kilograms divided by height in meters squared.
Table 3. Data for Dementia in Men
With Depressive Symptoms
Standard Modela,b Extended Modela,c
All dementiad 2.5 (1.5-4.1)e 2.2 (1.3-3.7)f
Pure ADd 3.0 (1.5-5.9)f 2.9 (1.4-5.9)f
Vascular dementia 2.2 (0.6-7.4) 1.3 (0.3-5.8)
Mixed ADd 2.9 (1.6-5.2)e 2.8 (1.5-5.1)f
Abbreviations: mixed AD, all Alzheimer disease including those with
cerebrovascular disease; pure AD, Alzheimer disease without apparent
cerebrovascular disease.
aData are given as hazard ratio (95% confidence interval). The reference
group was nondepressed men.
bAdjusted for age at examination 4, educational level, and self-reported
memory deterioration at baseline.
cAdjusted for age at examination 4, educational level, self-reported
memory deterioration at baseline, midlife systolic and diastolic blood
pressure, diabetes mellitus, smoking status, cholesterol level at examination
4, body mass index at examination 4, and stroke history.
dThe interaction term (depression  apolipoprotein E ε4) is significant in
the standard and extended models (P .01 for both).
eP .001.
fP .01.
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Figure. Cumulative hazard estimates for all types of dementia (log-rank test
for equality of survivor functions: 23=27.55, P .001). Neither refers to men
without depressive symptoms and apolipoprotein ε4 (APOE ε4) negative;
only e4, men without depressive symptoms and APOE ε4 positive; only Dep,
men with depressive symptoms and APOE ε4 negative; and both, men with
depressive symptoms and APOE ε4 positive.
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tia symptoms. In the present study, we excluded pos-
sible cognitively impairedmen from the analytical sample
and adjusted for the degree of self-reportedmemory prob-
lems and years of education to examine depression’s causal
relationship on dementia. Second, some research-
ers2,24,25 have suggested the possibility of a neurotoxic effect
of depression, such as hypothalamus–pituitary–adrenal
cortisol–induced hippocampal atrophy or lowered brain-
derived neurotrophic factor levels. Third, the associa-
tion between depression and dementia may be con-
founded by shared environmental or genetic factors. The
apolipoprotein genotype is an important candidate for
shared risk factors; however,most studies7,8,26,27 have found
no association betweenAPOE and depression. Last, it has
been proposed that vascular disease is the underlying con-
dition and may play a mediating role in the depression-
dementia causal relationship.22,28 In fact, some stud-
ies29,30 indicate that AD and depression share risk factors
for vascular disease. Atherosclerotic change starts in the
20s, and by 70 or 80 years of age, most individuals have
significant atherosclerosis.30 Cerebrovascular atheroscle-
rosis, arteriosclerosis, and aging-related degenerative
changes (such as amyloid deposition and neurofibril-
lary tangles) are all commonly found in the elderly popu-
lation without dementia.31,32 Recent studies33 empha-
size the important contribution of the vascular component
to AD, not only as a primary cause of dementia but also
as a cofactor in degenerative dementias. The clinical dis-
tinction between AD and vascular dementia may be dif-
ficult because the incidence of AD and the severity of ath-
erosclerotic change increase with aging and are often
found to coexist in elderly persons.34 On the other hand,
the association between depression and deep white mat-
ter lesions has been reported.35,36 However, this under-
lying vascular disease hypothesis remains inconclusive.
Recently, a large prospective study37 found no contribu-
tion of vascular disease to the depression-dementia as-
sociation, reporting that depression increased the risk of
mild cognitive impairment independent of underlying vas-
cular disease.
Apolipoprotein E plays an important role in lipid trans-
port andmetabolism, and previous studies38,39 have found
a significant association between the APOE ε4 allele and
hypercholesterolemia and increased risk of cardiovascu-
lar disease. Haan et al40 reported the modifiable effect of
the APOE ε4 allele on the association between athero-
sclerosis and cognitive decline. They also suggested an
important role for vascular diseases in dementia inde-
pendent of theAPOE ε4 allele because they found amuch
higher risk in individuals with severe atherosclerosis but
without the APOE ε4 allele.40 The ABI significantly in-
creased across 3 strata (from neither to single to both)
in the baseline characteristic analysis, with the degree of
atherosclerotic change being significantly higher in men
with both factors. However, adjustment for cardiovas-
cular risk factors did not substantially alter the results
of the survival analyses.
This study is unique and has several strengths. It is
based on a large, well-characterized cohort, allowing us
to study the independent and interactive effects of de-
pression and APOE ε4 status on dementia and its sub-
types, and we controlled for a variety of possible con-
founding factors. In addition, we used a well-structured
dementia diagnostic system, and the analytical sample
Table 4. Data for Incident Dementia and Its Subtypes by the Presence of Depressive Symptoms and APOE 4a
Hazard Ratio (95% Confidence Interval)
Neither Only e4 Only Dep Both
All dementia
No. of participants 1439 324 146 23
Standard model 1 [Reference] 1.1 (0.6-1.7) 1.9 (1.1-3.4)b 7.2 (3.1-16.8)c
Extended model 1 [Reference] 1.1 (0.6-1.8) 1.6 (0.8-3.0) 7.1 (3.0-16.7)c
Pure AD
No. of participants 1397 318 140 21
Standard model 1 [Reference] 1.5 (0.7-3.0) 2.3 (1.0-5.3)b 12.6 (4.4-37.0)c
Extended model 1 [Reference] 1.6 (0.8-3.1) 2.2 (0.9-5.2) 13.0 (4.3-39.5)c
Vascular dementia
No. of participants 1382 307 135 18
Standard model 1 [Reference] NA 1.3 (0.3-5.8) 5.2 (0.7-40.1)
Extended model 1 [Reference] NA 0.6 (0.1-4.8) 4.1 (0.5-33.7)
Mixed AD
No. of participants 1408 321 142 22
Standard model 1 [Reference] 1.4 (0.8-2.6) 2.3 (1.1-4.7)b 10.7 (4.2-27.3)c
Extended model 1 [Reference] 1.5 (0.8-2.7) 2.1 (0.9-4.5) 10.4 (3.9-27.4)c
Abbreviations: APOE ε4, apolipoprotein E ε4; mixed AD, all Alzheimer disease including those with cerebrovascular disease; NA, not applicable owing to the
small number; pure AD, Alzheimer disease without apparent cerebrovascular disease.
aNeither refers to men without depressive symptoms and APOE ε4 negative; only e4, men without depressive symptoms and APOE ε4 positive; only Dep, men
with depressive symptoms and APOE ε4 negative; and both, men with depressive symptoms and APOE ε4 positive. The standard model was adjusted for age at
examination 4, educational level, and self-reported memory deterioration at baseline. The extended model was adjusted for age at examination 4, educational level,
self-reported memory deterioration at baseline, midlife systolic and diastolic blood pressure, diabetes mellitus, smoking status, cholesterol level at examination 4,
body mass index at examination 4, and stroke history.
bP .05.
cP .001.
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was well-defined to examine the effects of both risk fac-
tors. However, the study also has several limitations. First,
although the study sample is well-defined by exclusion
and adjustment procedures, there may be a type II error
if these processes are not sensitive enough to detect all
cases with depressive symptoms resulting from the cog-
nitive decline process. Moreover, although the study
sample was well-defined, 1802men were excluded from
the analytical sample. Given that this is nearly half of the
original HAAS cohort, and that some baseline differ-
ences exist between the analytical sample and excluded
individuals, there is a possibility that the exclusion pro-
cess might have affected the analyses. Second, our mea-
surement of depression describes only depression symp-
toms, which is not synonymous with clinical depression.
It is possible that the results may either underestimate
or overestimate the association between clinical depres-
sion and dementia. However, the presence of depres-
sion symptoms has been shown to be associatedwith sub-
sequent cognitive decline,41-44 and these results support
the interpretation that depressive symptoms may pre-
dict the development of dementia. Moreover, to identify
individuals at increased risk, it seems to be more prac-
tical to use a screeningmeasurement of depressive symp-
toms than to impose a full evaluation for depression.
Third, this cohort includes only men, and results may
not apply to women. Because it has been recognized that
depression is approximately twice as common in women
as inmen,45,46 further investigation in a cohort of women
is required to determine whether a similar relationship
exists among APOE, depressive symptoms, and demen-
tia. The underlying cause of a sex difference in depres-
sion is not yet fully understood and may include bio-
logical differences and the different social roles of men
and women and measurement issues.47 However, sev-
eral studies48-50 have found that the sex difference dimin-
ishes or disappears in persons older than 75 or 85 years.
Moreover, a recent report from the National Institute of
Mental Health51 suggested that there may be more de-
pression cases among men and emphasized the impor-
tance of detecting and treating undiagnosed cases. Fourth,
owing to the small number of menwith vascular demen-
tia, we could not estimate the risk inmenwhowereAPOE
ε4 allele positive. Last, these results do not provide the
long-term effect of early-onset depression on the brain
because they pertain to depressive status measured up
to approximately 6 years before diagnosis. However, it
has been suggested that neurobiologic change during the
process of depression may occur even in late-onset
depression.52
The present study suggests that the presence of the
APOE ε4 allelemay create the susceptible condition; how-
ever, depressive symptoms further increase the risk of
dementia. The multiplicative interaction effect between
both factors indicates a pathologic environment that is
more predisposing to dementia. Depressedmenwith the
APOE ε4 allele had a 7 times higher risk of dementia, and
even depressed men without genetic susceptibility had
a 1.5- to 2-fold increased risk compared with nonde-
pressed men. These findings suggest that APOE ε4 sta-
tus modifies the association between depressive symp-
toms and dementia in men. Because individuals with
depressive symptoms and theAPOE ε4 allele had amark-
edly increased risk of dementia, one might be especially
watchful for early signs of dementia in the older person
with depressionwho is also positive for theAPOE ε4 allele.
Submitted for Publication: October 7, 2007; final revi-
sion received January 25, 2008; accepted March 12,
2008.
AuthorAffiliations:PacificHealth Research Institute (Drs
Irie, Masaki, Petrovitch, Abbott, Ross, and White), De-
partment of Geriatric Medicine, John A. Burns School of
Medicine, University of Hawaii (Drs Masaki, Petrovitch,
Ross, andWhite), Kuakini Medical Center (Drs Masaki,
Petrovitch, andWhite), andHonoluluDepartment of Vet-
erans Affairs (Dr Ross), Honolulu, Hawaii; Centre of Na-
tional Research on Disability and Rehabilitation Medi-
cine, Mayne Medical School (Dr Irie) and School of
Human Movement Studies (Dr Taaffe), The University
of Queensland, Brisbane, Australia; Division of Biosta-
tistics and Epidemiology, School of Medicine, Univer-
sity of Virginia, Charlottesville (Dr Abbott); Depart-
ment of Health Science, Shiga University of Medical
Science, Otsu, Shiga, Japan (Dr Abbott); and Laboratory
of Epidemiology, Demography, and Biometry, National
Institute onAging,National Institutes ofHealth, Bethesda,
Maryland (Dr Launer).
Correspondence: Fumiko Irie, MD, PhD, MPH, Centre
of National Research on Disability and Rehabilitation
Medicine, Level 3, Mayne Medical School, The Univer-
sity of Queensland, Herston Road, Herston, Queens-
land, Australia 4006 (f.irie@uq.edu.au).
Author Contributions: Dr Irie had full access to all of
the data in the study and takes responsibility for the in-
tegrity of the data and the accuracy of the data analysis.
Financial Disclosure: None reported.
Funding/Support: This study was supported by con-
tract N01-AG-4-2149 and the Intramural Research Pro-
gram, National Institute on Aging, contract N01-HC-
05102 from theNationalHeart, Lung, and Blood Institute,
the National Institutes of Health, and the Japan Society
for the Promotion of Science.
Previous Presentation: This study was presented at
the Congress of the Royal Australian and New Zealand
College of Psychiatrists; May 3, 2007; Gold Coast,
Australia.
REFERENCES
1. Meeks TW, Ropacki SA, Jeste DV. The neurobiology of neuropsychiatric syn-
dromes in dementia. Curr Opin Psychiatry. 2006;19(6):581-586.
2. Green RC, Cupples LA, Kurz A, Auerbach S, Go R, Sadovnick D, Duara R, Kukull
WA, Chui H, Edeki T, Griffith PA, Friedland RP, Bachman D, Farrer L. Depression
as a risk factor for Alzheimer disease: the MIRAGE Study. Arch Neurol. 2003;
60(5):753-759.
3. Wilson RS, Barnes LL, Mendes de Leon CF, Aggarwal NT, Schneider JS, Bach J,
Pilat J, Beckett LA, Arnold SE, Evans DA, Bennett DA. Depressive symptoms, cog-
nitive decline, and risk of AD in older persons. Neurology. 2002;59(3):364-370.
4. Dal Forno G, Palermo MT, Donohue JE, Karagiozis H, Zonderman AB, Kawas CH.
Depressive symptoms, sex, and risk for Alzheimer’s disease. Ann Neurol. 2005;
57(3):381-387.
5. Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk
for Alzheimer disease: systematic review, meta-analysis, and metaregression
analysis. Arch Gen Psychiatry. 2006;63(5):530-538.
6. Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351(1):56-67.
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 65 (NO. 8), AUG 2008 WWW.ARCHGENPSYCHIATRY.COM
911
©2008 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
7. Scarmeas N, Brandt J, Albert M, Devanand DP, Marder K, Bell K, Ciappa A, Tycko
B, Stern Y. Association between the APOE genotype and psychopathologic symp-
toms in Alzheimer’s disease. Neurology. 2002;58(8):1182-1188.
8. Craig D, Hart DJ, McIlroy SP, Passmore AP. Association analysis of apolipopro-
tein E genotype and risk of depressive symptoms in Alzheimer’s disease. De-
ment Geriatr Cogn Disord. 2005;19(2-3):154-157.
9. Krishnan KR, Tupler LA, Ritchie JC Jr, McDonald WM, Knight DL, Nemeroff CB,
Carroll BJ. Apolipoprotein E-ε4 frequency in geriatric depression. Biol Psychiatry.
1996;40(1):69-71.
10. Rigaud AS, Traykov L, Caputo L, Coste J, Latour F, Couderc R, Moulin F, Boller
F, Forette F. Association of the apolipoprotein E ε4 allele with late-onset depression.
Neuroepidemiology. 2001;20(4):268-272.
11. Syme SL, Marmot MG, Kagan A, Kato H, Rhoads G. Epidemiologic studies of
coronary heart disease and stroke in Japanese men living in Japan, Hawaii and
California: introduction. Am J Epidemiol. 1975;102(6):477-480.
12. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between
midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia
Aging Study. JAMA. 1995;274(23):1846-1851.
13. White L, Petrovitch H, Ross GW, Masaki KH, Abbott RD, Teng EL, Rodriguez BL,
Blanchette PL, Havlik RJ, Wergowske G, Chiu D, Foley DJ, Murdaugh C, Curb JD.
Prevalence of dementia in older Japanese-American men in Hawaii: the Honolulu-
Asia Aging Study. JAMA. 1996;276(12):955-960.
14. White L, Launer L. Relevance of cardiovascular risk factors and ischemic cere-
brovascular disease to the pathogenesis of Alzheimer disease: a review of ac-
crued findings from the Honolulu-Asia Aging Study. Alzheimer Dis Assoc Disord.
2006;20(3)(suppl 2):S79-S83.
15. Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, Sugimoto K, Yamagu-
chi T, Sasaki H, Chiu D. The Cognitive Abilities Screening Instrument (CASI): a
practical test for cross-cultural epidemiological studies of dementia. Int
Psychogeriatr. 1994;6(1):45-58.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental
Disorders, Third Edition, Revised. Washington, DC: American Psychiatric As-
sociation; 1987.
17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical
diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group un-
der the auspices of Department of Health and Human Services Task Force on
Alzheimer’s Disease. Neurology. 1984;34(7):939-944.
18. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for
the diagnosis of ischemic vascular dementia proposed by the State of California
Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology. 1992;42
(3, pt 1):473-480.
19. Takeshita J, Masaki K, Ahmed I, Foley DJ, Li YQ, Chen R, Fujii D, Ross GW, Petro-
vitch H, White L. Are depressive symptoms a risk factor for mortality in elderly
Japanese American men? the Honolulu-Asia Aging Study. Am J Psychiatry. 2002;
159(7):1127-1132.
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene
amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545-548.
21. Murabito JM, Evans JC, Larson MG, Nieto K, Levy D, Wilson PW. The ankle-
brachial index in the elderly and risk of stroke, coronary disease, and death: the
Framingham Study. Arch Intern Med. 2003;163(16):1939-1942.
22. Geda YE, Knopman DS, Mrazek DA, Jicha GA, Smith GE, Negash S, Boeve BF,
Ivnik RJ, Petersen RC, Pankratz VS, Rocca WA. Depression, apolipoprotein E
genotype, and the incidence of mild cognitive impairment: a prospective cohort
study. Arch Neurol. 2006;63(3):435-440.
23. Sweet RA, Hamilton RL, Butters MA, Mulsant BH, Pollock BG, Lewis DA, Lopez
OL, DeKosky ST, Reynolds CF III. Neuropathologic correlates of late-onset ma-
jor depression. Neuropsychopharmacology. 2004;29(12):2242-2250.
24. Dwivedi Y, Rizavi HS, Conley RR, Roberts RC, Tamminga CA, Pandey GN. Al-
tered gene expression of brain-derived neurotrophic factor and receptor tyro-
sine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry. 2003;
60(8):804-815.
25. Rapp MA, Schnaider-Beeri M, Grossman HT, Sano M, Perl DP, Purohit DP, Gor-
man JM, Haroutunian V. Increased hippocampal plaques and tangles in patients
with Alzheimer disease with a lifetime history of major depression. Arch Gen
Psychiatry. 2006;63(2):161-167.
26. Lyketsos CG, Baker L, Warren A, Steele C, Brandt J, Steinberg M, Kopunek S,
Baker A. Depression, delusions, and hallucinations in Alzheimer’s disease: no
relationship to apolipoprotein E genotype. J Neuropsychiatry Clin Neurosci. 1997;
9(1):64-67.
27. Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Duara R. Apolipo-
protein-E (APO-E) genotype and symptoms of psychosis in Alzheimer’s disease.
Am J Geriatr Psychiatry. 1999;7(2):119-123.
28. Fuhrer R, Dufouil C, Dartigues JF. Exploring sex differences in the relationship
between depressive symptoms and dementia incidence: prospective results from
the PAQUID Study. J Am Geriatr Soc. 2003;51(8):1055-1063.
29. Iadecola C, Gorelick PB. Converging pathogenic mechanisms in vascular and neu-
rodegenerative dementia. Stroke. 2003;34(2):335-337.
30. Rasgon N, Jarvik L. Insulin resistance, affective disorders, and Alzheimer’s dis-
ease: review and hypothesis. J Gerontol A Biol Sci Med Sci. 2004;59(2):178-
183.
31. Korczyn AD. Alzheimer’s disease and vascular brain lesions. J Neurol Sci. 2005;
231(1-2):1-2.
32. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR.
Brain infarction and the clinical expression of Alzheimer disease: the Nun Study.
JAMA. 1997;277(10):813-817.
33. Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA. Cerebral infarc-
tions and the likelihood of dementia from Alzheimer disease pathology.Neurology.
2004;62(7):1148-1155.
34. Korczyn AD. The underdiagnosis of the vascular contribution to dementia. J Neu-
rol Sci. 2005;229-230:3-6.
35. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM. Cere-
bral white matter lesions and depressive symptoms in elderly adults. Arch Gen
Psychiatry. 2000;57(11):1071-1076.
36. Minett TS, Dean JL, Firbank M, English P, O’Brien JT. Subjective memory com-
plaints, white-matter lesions, depressive symptoms, and cognition in elderly
patients. Am J Geriatr Psychiatry. 2005;13(8):665-671.
37. Barnes DE, Alexopoulos GS, Lopez OL, Williamson JD, Yaffe K. Depressive symp-
toms, vascular disease, and mild cognitive impairment: findings from the Car-
diovascular Health Study. Arch Gen Psychiatry. 2006;63(3):273-279.
38. Lahoz C, Schaefer EJ, Cupples LA, Wilson PW, Levy D, Osgood D, Parpos S,
Pedro-Botet J, Daly JA, Ordovas JM. Apolipoprotein E genotype and cardiovas-
cular disease in the Framingham Heart Study. Atherosclerosis. 2001;154(3):
529-537.
39. McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ische-
mic cerebrovascular disease: a meta-analysis. Neurology. 1999;53(6):1308-
1311.
40. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE ε4 in
modulating effects of other risk factors for cognitive decline in elderly persons.
JAMA. 1999;282(1):40-46.
41. Raji MA, Reyes-Ortiz CA, Kuo YF, Markides KS, Ottenbacher KJ. Depressive symp-
toms and cognitive change in older Mexican Americans. JGeriatr Psychiatry Neurol.
2007;20(3):145-152.
42. Chodosh J, Kado DM, Seeman TE, Karlamangla AS. Depressive symptoms as a
predictor of cognitive decline: MacArthur Studies of Successful Aging. Am JGeri-
atr Psychiatry. 2007;15(5):406-415.
43. Paterniti S, Verdier-Taillefer MH, Dufouil C, Alperovitch A. Depressive symp-
toms and cognitive decline in elderly people: longitudinal study. Br J Psychiatry.
2002;181:406-410.
44. Yaffe K, Blackwell T, Gore R, Sands L, Reus V, Browner WS. Depressive symp-
toms and cognitive decline in nondemented elderly women: a prospective study.
Arch Gen Psychiatry. 1999;56(5):425-430.
45. Blehar MC, Oren DA. Gender differences in depression.MedscapeWomensHealth.
1997;2(2):3.
46. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce
PR, Karam EG, Lee CK, Lellouch J, Le´pine JP, Newman SC, Rubio-Stipec M, Wells
JE, Wickramaratne PJ, Wittchen H, Yeh EK. Cross-national epidemiology of ma-
jor depression and bipolar disorder. JAMA. 1996;276(4):293-299.
47. Romans SE, Tyas J, Cohen MM, Silverstone T. Gender differences in the symp-
toms of major depressive disorder. J Nerv Ment Dis. 2007;195(11):905-911.
48. Bergdahl E, Gustavsson JM, Kallin K, von Heideken Wa˚gert P, Lundman B, Bucht
G, Gustafson Y. Depression among the oldest old: the Umea˚ 85 study. Int
Psychogeriatr. 2005;17(4):557-575.
49. Van’t Veer-Tazelaar PJ, van Marwijk HW, Jansen AP, Rijmen F, Kostense PJ, van
Oppen P, van Hout HP, Stalman WA, Beekman AT. Depression in old age (75):
the PIKO study. J Affect Disord. 2008;106(3):295-299.
50. Stek ML, Gussekloo J, Beekman AT, van Tilburg W, Westendorp RG. Preva-
lence, correlates and recognition of depression in the oldest old: the Leiden 85-
plus study. J Affect Disord. 2004;78(3):193-200.
51. National Institute of Mental Health. Men and depression: 2005. http://www.nimh
.nih.gov/health/publications/men-and-depression/men-and-depression.shtml. Ac-
cessed December 10, 2007.
52. Alexopoulos GS. Vascular disease, depression, and dementia. J Am Geriatr Soc.
2003;51(8):1178-1180.
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 65 (NO. 8), AUG 2008 WWW.ARCHGENPSYCHIATRY.COM
912
©2008 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
